EM801 / BMS - LARVOL DELTA

ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma By Targeting Two Antigens (ASH 2022) - "However, despite exceptional overall response rates observed using CAR T cell therapies or bispecific antibodies, durable responses beyond 2 years are still limited (PFS below 40% for treatment with idecabtagene vicleucel1 or teclistamab2)...This low expression of targets in the MM population has been observed after treatment with CD38-targeted daratumumab4, and BCMA specific CAR T cells5...ISB 2001 was only modestly affected by soluble BCMA or APRIL when compared to EM801, demonstrating killing at 3 pM (EC50) in the presence of these soluble factors...Seckinger, A. et al. Cancer Cell 31, 396–410 (2017)."

IO biomarker • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology

ICHNOS SCIENCES PRESENTS DATA SUPPORTING THREE ONCOLOGY ASSETS AT ASH 2022 ANNUAL MEETING (PRNewswire) - "Ichnos Sciences Inc...shared data during an oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition supporting the advancement of its first-in-class TREAT™ trispecific antibody, ISB 2001, to a first-in-human clinical trial. Both IND and CTN filings are planned during the first quarter of calendar year 2023 and preparations for a Phase 1 clinical trial in relapsed/refractory multiple myeloma (RRMM) are under way....Preclinical data on ISB 2001 presented at ASH include: Higher killing potency of tumor cell lines across varying expressions of both BCMA and CD38 compared to teclistamab, alnuctamab and EM-801; Superior potency of ISB 2001 relative to teclistamab, with 100 percent complete responses resulting in tumor elimination in multiple myeloma in vivo models; Superior cytotoxicity over teclistamab in ex vivo assays in patient bone marrow aspirates representing different stages of MM progression..."

IND • New P1 trial • Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology